<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=150191"><dc:title>Testing a perfusion small-scale model in ambr 15 and tubespin bioreactors for CHO cell clone comparison</dc:title><dc:creator>Bokalj,	Bor	(Avtor)
	</dc:creator><dc:creator>Narat,	Mojca	(Mentor)
	</dc:creator><dc:creator>Svetina,	Monika	(Komentor)
	</dc:creator><dc:subject>bioprocesses</dc:subject><dc:subject>small scale</dc:subject><dc:subject>chinese hamster</dc:subject><dc:subject>ovary cells</dc:subject><dc:subject>clone comparison</dc:subject><dc:subject>perfusion</dc:subject><dc:subject>fed batch</dc:subject><dc:description>Small scale bioreactor systems are important in bioprocess development. They allow much faster bioprocess development, reduce development costs, and ultimately contribute significantly to the biopharmaceuticals developed. Automation is a key step in high-throughput systems because it can reduce the need for human intervention, as well as measurement and bioprocess errors. The thesis compares two small scale models (SSM) with one another in a clone comparison study. Fed batch SSMs were only used for the clone comparison, since they were previously evaluated in a separate study. Two separate clone groups, which were prepared through different procedures, were used for the clone comparison. After comparing all SSMs with one another, we observed that the ambr15 perfusion mimic bioprocess needs to be optimised further to achieve full implementation into a bioprocess development pipeline for high-density perfusion bioprocesses (HDPB). Viability and viable cell density of the CHO culture was not yet comparable to larger scale bioprocesses and TubeSpin system tests. During the clone comparison, we observed that both clone groups performed similarly in TubeSpins. On the other hand, when comparing separate clones, the best clone from Group 1 had a slight advantage in fed batch bioprocesses when it comes to IgG production, while the best clone from Group 2 had a slight advantage in HDPB IgG production. This was observed after comparing the best performing clones from each group and the bioprocess type. The top clone from clone group 2 achieved higher IgG concentration during the bioprocesses after 10 days of incubation. The same was true for the top clone from Group 1 in FB, where the best clone from Group 1 achieved higher IgG concentrations. In the near future, IgG quality will have to be evaluated in each of the bioprocess models in order to establish which CHO clones are the superior ones.</dc:description><dc:date>2023</dc:date><dc:date>2023-09-15 07:15:39</dc:date><dc:type>Magistrsko delo/naloga</dc:type><dc:identifier>150191</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
